Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
Currently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and...
Saved in:
| Main Authors: | E. L. Nasonov, T. V. Popkova, A. M. Lila |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01) -
Pharmacoeconomic analysis of rituximab and belimumab therapy in patients with systemic lupus erythematosus
by: D. A. Gerasimova, et al.
Published: (2024-10-01) -
PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. L. Nasonov, et al.
Published: (2014-06-01) -
RESULTS OF AN OBSERVATIONAL PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF BELIMUMAB (BENLYSTA®) IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL CLINICAL PRACTICE
by: E. A. Aseeva, et al.
Published: (2016-03-01) -
Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01)